MT. OLIVE – Catheter Precision, Inc., a medical machine and know-how firm targeted on cardiac electrophysiology, publicizes that its lead product, VIVO (View Into Ventricular Onset), can be featured in shows by three physicians working within the discipline of cardiac electrophysiology on the Sixth Annual Society of Cardiac Robotic Navigation (SCRN) assembly being held September 29-30 in Budapest, Hungary.
On September 12, 2022 privately held Catheter Precision introduced a definitive merger settlement with Ra Medical Programs (NYSE American: RMED), which, if accomplished, will end in a mixed publicly traded firm specializing in the cardiac electrophysiology market.
The VIVO shows on the SCRN assembly are as follows
Non-invasive Mapping for PVC Ablation, offered by Dr. Tamas Szili-Torok, Professor of Medication at Erasmus Medical Heart in Rotterdam, the Netherlands
Non-invasive Mapping for Robotic PVC Ablation: The Royal Brompton Expertise, offered by Dr. Jack Griffiths, Inside Medication Resident on the Royal Brompton Hospital in London, UK
Robotics and Non-invasive Mapping, offered by Dr. Leonor Parreira from Hospital La Luz in Lisbon, Portugal
‘These a number of shows at a prestigious international medical convention underscore the scientific acceptance and advantages of our product to prospects worldwide,’ mentioned David Jenkins, Catheter Precision CEO. ‘VIVO enhances using robotic catheter navigation for ventricular ablation procedures by offering perception into the ablation location and affected person anatomy prematurely of the ablation process.’
VIVO is a non-invasive 3D imaging system that permits physicians to establish the origin of arrhythmias pre-procedure, thereby streamlining workflow and lowering process time. VIVO has acquired advertising clearance from the U.S. FDA and has been awarded the CE mark. Catheter Precision intends to pursue a second technology of Amigo, a beforehand FDA-cleared and CE mark robotic arm that can be utilized to remotely management catheters outdoors of the process room. Moreover, Catheter Precision is working towards a business launch of a vessel closure machine, at present deliberate for the primary half of 2023.
Underneath the phrases of the definitive merger settlement with Ra Medical Programs, Catheter Precision will change into a completely owned subsidiary of Ra Medical Programs in a stock-for-stock reverse merger transaction. The merger is predicted to shut earlier than the top of 2022, topic to satisfying sure closing circumstances, together with the receipt of shareholder approval by each corporations.
In regards to the Society for Cardiac Robotics Navigation (SCRN) Assembly
The SCRN annual assembly offers physicians, engineers, scientists, allied professionals and others a discussion board for sharing particular information concerning the capabilities of assorted robotic strategies used within the therapy and diagnoses of arrhythmias. Applications are created to make clear each present applied sciences in addition to dialogue of future developments. The annual conferences will proceed to contribute to improvements to robotics within the medical discipline.
About Catheter Precision
Catheter Precision is an modern U.S.-based medical machine firm bringing new options to market to enhance the therapy of cardiac arrhythmias. It’s targeted on growing groundbreaking know-how for electrophysiology procedures by collaborating with physicians and repeatedly advancing its merchandise.
About Ra Medical Programs
Ra Medical Programs, Inc. (‘Ra Medical‘ or the ‘Firm’) is a medical machine firm that owns mental property associated to a complicated excimer laser-based platform to be used within the therapy of vascular immune-mediated inflammatory ailments. Its excimer laser and single-use catheter system, collectively known as the DABRA Excimer Laser System, is used as a software within the therapy of peripheral artery illness.
Cautionary Word Concerning Ahead-Trying Statements
This communication comprises forward-looking statements which embody, however usually are not restricted to, statements concerning anticipated timing, completion and results of the proposed Merger, future entry to capital markets, and the plans and expectations of the mixed firm concerning Catheter Precision’s merchandise, together with its plans, methods, projected timelines and estimated markets, for and/or associated to VIVO and the Amigo and vessel closure gadgets described above. These forward-looking statements are topic to the protected harbor provisions below the Non-public Securities Litigation Reform Act of 1995. The Firm’s and Catheter Precision’s expectations and beliefs concerning these issues could not materialize. Precise outcomes and outcomes could differ materially from these contemplated by these forward-looking statements on account of uncertainties, dangers and adjustments in circumstances, together with however not restricted to dangers and uncertainties associated to: the power of the events to consummate the proposed Merger, satisfaction of closing circumstances precedent to the consummation of the proposed Merger, potential delays in consummating the Merger and the power of the Firm and Catheter Precision to well timed and efficiently obtain the anticipated advantages of the Merger, together with the power of the mixed firm to entry the capital markets at such instances and in such quantities, and on such phrases, as wanted to fulfill the Web Money necessities of the Merger Settlement, execute its future enterprise methods and keep its itemizing on the NYSE American or different nationwide inventory change, potential utility of SEC and/or change ‘shell firm’ guidelines, and the power of the mixed firm to efficiently pursue its product strains within the method and within the timeframe described right here. The Merger Settlement comprises sure closing circumstances, together with a minimal prevailing inventory value for Ra Medical and Web Money quantity at closing, which don’t represent representations or covenants of both social gathering, and are topic to waiver by the events. If Ra Medical’s inventory value drops beneath sure ranges, the quantity of merger consideration, if any, acquired by Catheter stockholders can be adversely impacted. The events have reserved the proper to waive circumstances to the closing of the Merger and revise the Merger Settlement. Extra dangers and uncertainties that would trigger precise outcomes and outcomes to vary materially from these contemplated by the forward-looking statements are included below the caption ‘Danger Elements’ and elsewhere within the Firm’s most up-to-date filings with the SEC, together with the Firm’s Quarterly Report on Kind 10-Q for the quarter ended June 30, 2022, the Present Studies on Kind 8-Okay, together with the Present Report on Kind 8-Okay filed on September 12, 2022, and any prior or subsequent experiences on Kind 10-Okay, Kind 10-Q or Kind 8-Okay filed with the SEC occasionally and accessible at www.sec.gov. Vital enterprise and monetary details about Catheter Precision’s enterprise and the associated dialogue and evaluation of economic situation and outcomes of operations of Catheter Precision is about forth within the Present Report on Kind 8-Okay being filed on September 12, 2022 and the reveals thereto and must be learn at the side of the Catheter Precision Monetary Statements and the professional forma monetary statements for the mixed firm which might be hooked up as reveals thereto. Dangers and uncertainties associated to the Merger, Catheter Precision, and the projections and estimates described above which will trigger precise outcomes to vary materially from these expressed or implied in any forward-looking assertion are included ‘Danger Elements – Danger Associated to the Merger with Catheter Precision and – Dangers Associated to Our Analysis of Strategic Options for our Legacy Property,’ and ‘Danger Elements – Dangers Associated to the Enterprise of Catheter Precision,’ that are filed because the reveals to the Present Report on Kind 8-Okay filed on September 12, 2022. These paperwork may be accessed on the Firm’s Investor Relations web page at https://ir.ramed.com/ by clicking on the hyperlink titled ‘SEC Filings.’ The dangers and uncertainties could also be amplified by the COVID-19 pandemic, which has precipitated vital financial uncertainty, and ongoing volatility within the inventory markets and the U.S. economic system on the whole. The extent to which the COVID-19 pandemic impacts the Firm’s and Catheter Precision’s companies, operations, and monetary outcomes, together with the length and magnitude of such results, will rely on quite a few components, that are unpredictable, together with, however not restricted to, the length and unfold of the outbreak, its severity, the actions to comprise the virus or deal with its impression, and the way rapidly and to what extent regular financial and working circumstances can resume.
The forward-looking statements included on this communication are made solely as of the date hereof. The Firm and Catheter Precision assume no obligation and don’t intend to replace these forward-looking statements, besides as required by regulation.
Disclaimer
This press launch pertains to a proposed enterprise mixture between the Firm and Catheter Precision. This doc doesn’t represent a suggestion to promote or change, or the solicitation of a suggestion to purchase or change, any securities, nor shall there be any sale of securities in any jurisdiction wherein such provide, sale or change can be illegal previous to registration or qualification below the securities legal guidelines of any such jurisdiction.
Contact:
Missiaen Huck
Tel: 973-691-2000
Electronic mail: mhuck@catheterprecision.com
